PARP

10 stories · following the connections

Business

TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany

By Nasdaq OMXDec 15, 2017, 9:00 AM UTC

Business

TESARO Receives Positive CHMP Opinion for ZEJULA®

By Nasdaq OMXSep 15, 2017, 11:45 AM UTC

Business

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

By Nasdaq OMXMay 25, 2017, 8:19 PM UTC

Business

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

By Nasdaq OMXMay 25, 2017, 8:19 PM UTC

Business

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

By Nasdaq OMXMay 25, 2017, 8:19 PM UTC

Business

TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.

By Nasdaq OMXApr 19, 2017, 8:16 PM UTC

Business

TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.

By Nasdaq OMXApr 19, 2017, 8:16 PM UTC

Business

Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO

By Nasdaq OMXMar 13, 2017, 3:10 PM UTC